Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17739915 | 0.92 | TTR (0.36) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL17739959 | 0.92 | TTR (0.36) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19703717 | 0.92 | TTR (0.36) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19703693 | 0.90 | ALDH1A1 (0.39) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19703595 | 0.89 | TTR (0.34) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19698200 | 0.87 | TTR (0.35) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19698213 | 0.87 | TTR (0.35) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL17739997 | 0.87 | HRH4 (0.40) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19703961 | 0.87 | DRD2 (0.35) | TTRIL2DRD2DRD4DRD3 | |
| SCHEMBL19703577 | 0.85 | TTR (0.43) | TTRIL2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | TTR 2493/4885IL2 1226/4885DRD2 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.